【摘要】 目的观察参红胶囊联合化疗药物对中晚期肿瘤患者疗效、症状改善和免疫功能的影响。方法将598例确诊肿瘤患者随机分为两组,205例单纯使用化疗组,393例参红胶囊加化疗组。连续治疗60d后,观察疗效、症状改善情况、卡氏评分、免疫功能、外周血白细胞计数等。结果与对照组相比,参红胶囊组肿瘤患者总缓解率42.0%;疼痛、咳嗽、乏力和食欲不振平均改善率为71.9%;卡氏评分提高27.0%;CD3+、CD4+数量增加11.6%和19.3%,CD8+降低22.6%,CD4+/CD8+增加54.2%;NK细胞活性和巨噬细胞功能明显提高,IgG和IgA含量增加。结论参红胶囊联合化疗提高中晚期恶性肿瘤患者的疗效。这可能与其提高患者免疫功能有关。更多还原

【Abstract】 Objective To observe the effects of Shenhong (SH) combined with chemotherapeutic drugs on curative effect, symptoms improvement, and immunology function in metaphase or terminal cancer patients.Methods All 598 patients were divided into two groups. The control group had 205 patients treated with chemotherapeutic drugs. The SH-treated group had 393 patients treated with SH combined with chemotherapeutic drugs. Results Compared with control patients, the total remission was 42.0% in SH-treated patients. The improvement rates of pain, cough, debilitation, and anepithymia were 71.9%. The Karnofsky grade was increased by 27.0%. CD+3 and CD+4 were increased by 11.6% and 19.3%, but CD+8was decreased by 22.6% at the same time. The patients CD+4 / CD+8 was enhanced by 54.2%, while the NK cell activity and marophage phagocysis were significantly improved. The content of Ig G and Ig A were increased in the same group. Conclusion The curative effect of SH combined with chemotherapeutic drugs was higher than that of control group. The therapeutic effect of SH is explained by its potential regulation activity on immun system.更多还原